Crinetics Pharmaceuticals (CRNX) Return on Capital Employed (2018 - 2026)
Crinetics Pharmaceuticals' quarterly Return on Capital Employed came in at 45.76% in Q1 2026, down 1766.0% year-on-year from 2.75% in Q1 2025, and up 4.72% quarter-over-quarter from 48.02% in Q4 2025.
Crinetics Pharmaceuticals has reported Return on Capital Employed for 9 years, with the latest figure at 45.76% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed fell 1766.0% year-over-year to 45.76%; the trailing twelve-month figure through Mar 2026 stood at 45.76% (down 1766.0% YoY), and the FY2025 full-year result was 43.23%, down 849.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 45.76%, up from 48.02% in the prior quarter.
- The five-year high for Return on Capital Employed was 28.1% in Q1 2025, with the low at 70.84% in Q2 2023.
- Average Return on Capital Employed over 5 years is 41.52%, with a median of 38.58% recorded in 2022.
- Year-over-year, Return on Capital Employed sank 3226 bps in 2023 and soared 4004 bps in 2024.
- Tracing CRNX's Return on Capital Employed over 5 years: stood at 49.26% in 2022, then gained by 24 bps to 37.44% in 2023, then climbed by 20 bps to 30.09% in 2024, then plunged by 60 bps to 48.02% in 2025, then gained by 5 bps to 45.76% in 2026.
- The last three Return on Capital Employed figures came in at 45.76% (Q1 2026), 48.02% (Q4 2025), and 40.89% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Crinetics Pharmaceuticals | 3.59 Bn | 3.59 Bn | 10.53 Mn | -45.76% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -45.76% |
| Dec 31, 2025 | -48.02% |
| Sep 30, 2025 | -40.89% |
| Jun 30, 2025 | -33.65% |
| Mar 31, 2025 | -28.10% |
| Dec 31, 2024 | -30.09% |
| Sep 30, 2024 | -34.75% |
| Jun 30, 2024 | -30.80% |
| Mar 31, 2024 | -32.87% |
| Dec 31, 2023 | -37.44% |
| Sep 30, 2023 | -48.60% |
| Jun 30, 2023 | -70.84% |
| Mar 31, 2023 | -59.34% |
| Dec 31, 2022 | -49.26% |
| Sep 30, 2022 | -39.92% |
| Jun 30, 2022 | -38.58% |
| Mar 31, 2022 | -36.85% |
| Dec 31, 2021 | -40.77% |
| Sep 30, 2021 | -49.13% |
| Jun 30, 2021 | -50.05% |
| Mar 31, 2021 | -49.06% |
| Dec 31, 2020 | -41.32% |
| Sep 30, 2020 | -34.21% |
| Jun 30, 2020 | -40.56% |
| Mar 31, 2020 | -52.91% |
| Dec 31, 2019 | -42.02% |
| Sep 30, 2019 | -34.09% |
| Jun 30, 2019 | -26.69% |
| Mar 31, 2019 | -20.73% |
| Dec 31, 2018 | -17.28% |
| Sep 30, 2018 | -18.12% |